Tirzepatide differs from semaglutide in a structural way that is easy to state and worth understanding: it engages two receptors instead of one. Your gut releases two incretin hormones after a meal — GLP-1 and GIP. Most therapies in this category mimic GLP-1 alone. Tirzepatide is a single molecule that binds both receptors, which means it acts on two parallel signaling pathways involved in insulin response, appetite regulation, and how the body handles nutrients after eating. Dosing is once weekly, titrated gradually, and every protocol is physician-reviewed with ongoing monitoring.
Jacksonville Beach:
904.372.4401
Riverside:
904.337.0746
- Metabolic & Weight Management
Tirzepatide
- Dual GIP, GLP-1 Receptor Agonist
Benefits
Supports appetite regulation and metabolic signaling through two incretin receptor pathways.
- Engages both GIP and GLP-1 receptors rather than a single pathway
- Once-weekly dosing rather than daily administration
- Associated with glucose-dependent insulin response
- Associated with slowed gastric emptying and extended satiety signaling
- Physician-reviewed protocol with gradual dose titration
Safety Information
Nausea, vomiting, diarrhea, and constipation are the most commonly reported effects and are typically most pronounced early in a protocol and during dose increases. Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Discuss any history of pancreatitis, gallbladder disease, gastroparesis, or diabetic retinopathy with your provider. Not for use during pregnancy or breastfeeding. This protocol requires clinical evaluation and ongoing provider monitoring.
Regimen
Once-weekly injection on the same day each week. Dosing begins low and is titrated upward by your provider over the course of the protocol. Timing relative to meals is not required.
How to Take
Subcutaneous injection near the lower abdomen, outer thigh, or back of the upper arm. Use sterile technique. Rotate injection sites weekly.
How It Works
Tirzepatide is a single peptide engineered to activate two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both hormones are released by the intestine in response to food, and both are associated with insulin signaling, but they act through separate receptors and separate downstream pathways. GLP-1 receptor activity is associated with glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and hypothalamic appetite signaling. GIP receptor activity is associated with insulin response and with signaling in adipose tissue related to nutrient handling. Engaging both is the structural distinction between tirzepatide and single-agonist compounds.
Tirzepatide has been studied in a large program of randomized controlled trials for type 2 diabetes and for chronic weight management, and FDA-approved formulations exist for both. The dual-receptor mechanism is what distinguishes it in the research: it activates both the GLP-1 receptor and the GIP receptor, and head-to-head trial data has compared it directly against single-agonist GLP-1 therapy. The side effect profile mirrors the GLP-1 class — gastrointestinal effects that are most pronounced during titration — and it carries the same thyroid and pancreatitis contraindications. Compounded tirzepatide is a different product from the FDA-approved formulations. It is prepared by a licensed compounding pharmacy for an individual patient under prescription, is not FDA-approved, and its availability through compounding is more limited than semaglutide’s. It requires a clinical evaluation, documented medical need, and ongoing provider monitoring.
FAQs
What is tirzepatide?
A single peptide that activates two incretin receptors — GLP-1 and GIP. Both hormones are released by the gut after eating and both are involved in insulin response and appetite signaling, but they work through separate pathways.
How is tirzepatide different from semaglutide?
Semaglutide activates one receptor, GLP-1. Tirzepatide activates two, GLP-1 and GIP. The GIP pathway adds signaling related to insulin response and nutrient handling in fat tissue. Both are dosed once weekly.
How is tirzepatide dosed?
Once weekly by subcutaneous injection, on the same day each week. Dosing starts low and is increased gradually by your provider to minimize gastrointestinal side effects.
What are the side effects of tirzepatide?
Nausea, vomiting, diarrhea, and constipation are most common, especially during dose increases. Not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Provider review required for any history of pancreatitis, gallbladder disease, or diabetic retinopathy.
Is compounded tirzepatide the same as the FDA-approved medication?
No. Compounded tirzepatide is prepared by a licensed compounding pharmacy for an individual patient under prescription and is not FDA-approved. Availability through compounding is more limited than for semaglutide. Your provider will discuss which option applies to you.
How to Use Your Peptides
Before you get started with your peptide protocol, we recommend reviewing our Injection Guide to ensure safe and effective use. This quick-reference document walks you through proper subcutaneous injection technique, storage tips, and other best practices.
Each protocol below includes recommended timing, injection instructions, safety notes, and how the peptides work in your body. As always, please follow your provider’s guidance, and please reach out with any questions!
Book a Consultation
More Like Tirzepatide
Not all patients qualify for all treatments – book a free consultation to find out what program is right for you.